Chinese Hamster Ovary (i.e., Cho) Patents (Class 435/358)
-
Publication number: 20140315804Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.Type: ApplicationFiled: March 13, 2014Publication date: October 23, 2014Applicant: GENZYME CORPORATIONInventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
-
Patent number: 8865421Abstract: Methods and genetic constructs are provided for detecting the binding of nuclear hormone receptors to a coactivator/corepressor. The methods employ enzyme fragment complementation using fragments of ?-galactosidase as the detection system. Cells are transformed to express the large fragment of ?-galactosidase fused to a member of the complex with NHR for initiation of transcription and have it localized in the nucleus and to express the small fragment of ?-galactosidase fused to the nuclear hormone receptor for binding to the member upon stimulation with a ligand.Type: GrantFiled: June 23, 2009Date of Patent: October 21, 2014Assignee: DiscoveRx CorporationInventors: Thomas S. Wehrman, Chin Yee Loh, Mahesh Mathrubutham, Keith R. Olson
-
Publication number: 20140308704Abstract: The present invention relates to a cell line in which an expression construct is introduced into a genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus E1 coding gene sequence of SEQ ID NO:1 operatively linked to the promoter. According to the present invention, the cell line of the present invention is a novel cell line which is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the present invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus.Type: ApplicationFiled: November 22, 2012Publication date: October 16, 2014Inventors: Seung Shin Yu, Chang-Wan Joo, Jin-A Chae, Yeon Suk Cha
-
Patent number: 8858928Abstract: The present invention provides compositions comprising retroviral vectors, transduced cells, and methods of using the same for gene therapy. In particular, the present invention relates to lentiviral vectors and cells transduced with those vectors to provide gene therapy to subjects having an adrenoleukodystrophy and/or adrenomyeloneuropathy.Type: GrantFiled: June 8, 2012Date of Patent: October 14, 2014Assignee: bluebird bio, Inc.Inventors: Maria Joann Denaro, Mitchell Howard Finer, Gabor Veres, Julian Down
-
Publication number: 20140301974Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.Type: ApplicationFiled: January 30, 2014Publication date: October 9, 2014Applicant: Amunix Operating Inc.Inventors: Volker Schellenberger, Joshua Silverman, Chia-Wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
-
Publication number: 20140303084Abstract: Provided are pro-coagulant compounds (e.g., pro-coagulant peptides or peptide derivatives) and methods of using and making those compounds. Further provided are conjugates between a pro-coagulant compound of the present disclosure (e.g., pro-coagulant peptide or peptide derivative) and a polypeptide selected from FIX, FVIIa, FVIII, and platelet targeting moieties (e.g., PDG-13), wherein the compound is linked to the polypeptide optionally via a linker. The compounds and conjugates are useful for the treatment of coagulation disorders, such as hemophilia A and hemophilia B. Further provided are methods of using and making the conjugates.Type: ApplicationFiled: June 9, 2012Publication date: October 9, 2014Applicant: Biogen IDEC MA Inc.Inventors: Karina Thorn, Garabet G. Toby, Adam R. Mezo
-
Patent number: 8853154Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: GrantFiled: September 12, 2013Date of Patent: October 7, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.
-
Publication number: 20140298505Abstract: The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease.Type: ApplicationFiled: June 6, 2012Publication date: October 2, 2014Inventor: Ralf Kühn
-
Publication number: 20140296242Abstract: Some embodiments of this invention include methods for treating disease and methods for administering a compound of the invention. In some aspects of the invention, diseases can be treated by administration of compositions comprising a compound of the invention. Pharmaceutical compositions of some embodiments of the present invention comprise a compound of the invention.Type: ApplicationFiled: April 27, 2012Publication date: October 2, 2014Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: J. Chistopher States, Ben Frazier Taylor, John O. Trent
-
Publication number: 20140295502Abstract: The present invention generally relates to methods of making cDNA molecules and cDNA libraries. The invention also relates to cDNA molecules and cDNA libraries produced according to these methods, as well as to vectors and host cells containing such cDNA molecules and libraries. The invention also relates to kits for making the cDNA molecules and libraries of the invention.Type: ApplicationFiled: May 13, 2014Publication date: October 2, 2014Inventors: Wu-Bo LI, Joel Jessee, Christian Gruber
-
Publication number: 20140295544Abstract: The present invention relates to fluorescent proteins, in particular green fluorescent proteins (GFPs), with increased activity in cells, and thus increased signal strength. A further aspect of the present invention relates to the use of peptides for increasing the expression and/or stability of a protein in a cell.Type: ApplicationFiled: June 13, 2014Publication date: October 2, 2014Inventor: Khalid S. Abu KHABAR
-
Publication number: 20140295457Abstract: The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.Type: ApplicationFiled: October 11, 2012Publication date: October 2, 2014Inventors: Mark Broenstrup, Claudia Koenig, Luigi Toti, Joachim Wink, Wulf Leuschner, Johann Gassenhuber, Rolf Müller, Silke Wenzel, Tina Binz, Carsten Volz
-
Publication number: 20140295545Abstract: A pre-programmed non-feedback continuous feeding method based on mass balance of the substrate in the bioreactor for use in culture growth and maintenance is provided. The disclosed method does not rely on instrument, probe or operator feedback. The method provides an efficient and effective alternative to bolus feeding.Type: ApplicationFiled: September 14, 2012Publication date: October 2, 2014Applicant: AMGEN INC.Inventors: Henry Lin, Jeremy Bezaire
-
Patent number: 8846603Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: GrantFiled: March 11, 2011Date of Patent: September 30, 2014Assignee: Synageva Biopharma Corp.Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
-
Patent number: 8846373Abstract: The present invention relates to new methods to promote sialylation of glycoconjugates, including recombinant glycoproteins, in glycoconjugate production systems. The invention relates to methods to promote efficient glycoconjugate sialylation in recombinant expression systems, by providing simpler and more economical ways to produce large intracellular pools of sialic acid precursors. The invention is directed to nucleic acids, vectors, and cells harboring vectors comprising nucleic acids encoding enzymes involved in the synthesis of sialic acid precursors, and cells harboring these nucleic acids in combination with nucleic acids encoding glycosyltransferases, including sialyltransferases, to facilitate the production of humanized recombinant glycoproteins in bacterial, fungal, plant, and animal cell expression systems.Type: GrantFiled: July 27, 2012Date of Patent: September 30, 2014Assignee: The University of WyomingInventors: Christoph Geisler, Donald Jarvis
-
Publication number: 20140287497Abstract: The present invention relates to regulation of cold sensation and pain. More particularly, the present invention is directed to nucleic acids encoding a member of the transient regulatory protein family, CMR1, which is involved in modulation of the perception of cold sensations and pain. The invention further relates to methods for identifying and using agents that modulate cold responses and pain responses stimulated by cold via modulation of CMR1 and CMR1-related signal transduction.Type: ApplicationFiled: April 8, 2014Publication date: September 25, 2014Applicant: The Regents of the University of CaliforniaInventors: David Julius, David D. McKemy, Werner M. Neuhausser
-
Publication number: 20140286898Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Applicant: Amgen Inc.Inventors: Marc A. GAVIN, Gunasekaran KANNAN, Li LI, Joshua T. PEARSON, Margaret KAROW
-
Publication number: 20140288008Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Applicants: Daiichi Sankyo Company, Limited, Pieris AGInventors: GABRIELE MATSCHINER, CHRISTINE ROTHE, ANDREAS HOHLBAUM, ANDREA ALLERSDORFER, RACHIDA SIHAM BEL AIBA, MARLON HINNER, ALEXANDER WIEDENMANN, SHINJI YAMAGUCHI, TAKAHIDE ABURATANI, RYUJI HASHIMOTO, TOHRU TAKAHASHI, CHIKAKO NAGASAKI, FUTOSHI NARA, TOMOHIRO NISHIZAWA
-
Publication number: 20140288000Abstract: Compositions and methods are disclosed that relate to novel plasmin-inhibiting polypeptides that are structural variants of a human TFPI-2 Kunitz-type proteinase first inhibitor domain (KD1). The polypeptides are potent plasmin inhibitors and in certain embodiments have anti-fibrinolytic activity and/or decreased anti-coagulation activity relative to wild-type TFPI-2 KD1 and are not highly immunogenic. The plasmin-inhibiting polypeptides will find uses as anti-cancer agents, as antifibrinolytic agents, as protease inhibitors, and in other contexts.Type: ApplicationFiled: March 14, 2014Publication date: September 25, 2014Applicant: The Regents of the University of CaliforniaInventor: S. Paul Bajaj
-
Patent number: 8841089Abstract: The present invention relates to polynucleotides comprising a first nucleic acid sequence for a chromatin element, which is capable of enhancing expression, and at least one second nucleic acid sequence comprising a curved origin motif. Furthermore, the invention relates to a host cell, a non-human transgenic organism, a vector and a kit comprising the aforementioned polynucleotide. Moreover, the invention relates to methods for expressing a polynucleotide of interest.Type: GrantFiled: March 28, 2008Date of Patent: September 23, 2014Assignee: Hochschule MannheimInventors: Manfred Frey, Heiko Flammann, Mathias Hafner
-
Publication number: 20140273206Abstract: The current disclosure provides a method for the creation of a high-density cryopreserved cell bank using perfusion culture techniques and non-centrifugal concentration of cells. Methods of production using this high-density cryopreserved cell bank are also provided.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Genzyme CorporationInventors: Xiaoxia JIN, Haodi DONG, Claudia BUSER
-
Publication number: 20140273096Abstract: The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.Type: ApplicationFiled: April 9, 2014Publication date: September 18, 2014Applicant: CSL Behring GmbHInventors: Stefan SCHULTE, Thomas WEIMER, Hubert METZNER
-
Publication number: 20140273208Abstract: The invention provides expression vectors and host cells for high-level expression of recombinant proteins. The expression vectors comprise Chinese hamster ovary elongation factor 1-? (CHEF1) transcriptional regulatory DNA elements and a cytomegalovirus (CMV) promoter and/or a human adenovirus tripartite leader (AdTPL) sequence. The invention achieves increased protein expression and better productivity of host cells compared to previously described expression systems.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicant: CMC ICOS BIOLOGICS, INC.Inventor: Howard R. Clarke
-
Publication number: 20140274874Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: AMGEN INC.Inventors: Randal R. KETCHEM, Jason Charles O'NEILL, Jeonghoon SUN
-
Publication number: 20140274782Abstract: Methyl-lysine affinity reagents created by engineering the 3×MBT methyl-lysine binding domain repeat of lethal (3) malignant brain tumor-like protein 1 (L3MBTL1) are disclosed. In particular, the invention relates to affinity reagents and affinity chromatography media comprising the 3×MBT domain repeat and methods of using such affinity reagents in detection, purification, and proteomic profiling of methylated proteins and peptides.Type: ApplicationFiled: March 15, 2014Publication date: September 18, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Scott M. Carlson, Or Gozani, Kaitlyn E. Moore
-
Publication number: 20140273097Abstract: Disclosed herein are methods and compositions for inactivating a FUT8 gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.Type: ApplicationFiled: May 28, 2014Publication date: September 18, 2014Applicant: Sangamo BioSciences, Inc.Inventors: Trevor Collingwood, Gregory J. Cost
-
Publication number: 20140273204Abstract: The invention relates to recombinant expression vectors encoding a low molecular weight peptide isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Inventors: John M. Stewart, Bradley J. Steeves, Karl Vernes
-
Publication number: 20140272932Abstract: The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.Type: ApplicationFiled: December 23, 2013Publication date: September 18, 2014Applicant: Abbott LaboratoriesInventors: A. Scott Muerhoff, Christopher Marohnic, Larry Birkenmeyer, John Prostko, Felisha Bogdan, Robin Gutierrez
-
Patent number: 8835133Abstract: The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.Type: GrantFiled: March 7, 2013Date of Patent: September 16, 2014Assignee: Genentech, Inc.Inventors: Sherman Fong, Mark S. Dennis
-
Publication number: 20140255401Abstract: The present invention relates to Kv1.3 antagonists, and polynucleotides encoding them, and methods of making and using the foregoing.Type: ApplicationFiled: January 24, 2014Publication date: September 11, 2014Applicant: Janssen Biotech, Inc.Inventors: Ellen Chi, Wilson Edwards, Chichi Huang, Wai-Ping Leung, Ronald Swanson, Alan Wickenden
-
Publication number: 20140255990Abstract: The present invention provides isolated polynucleotides that can serve as translation enhancing elements and their use in protein expression reagents and methods.Type: ApplicationFiled: October 26, 2012Publication date: September 11, 2014Applicant: Arizona Board of RegentsInventors: John Chaput, Bertram Jacobs, Brian Wellensiek, Julia Flores
-
Publication number: 20140248665Abstract: The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns.Type: ApplicationFiled: December 19, 2013Publication date: September 4, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Barbara ENENKEL
-
Publication number: 20140248259Abstract: Factor X/Xa variants and methods of use thereof are disclosed.Type: ApplicationFiled: October 1, 2012Publication date: September 4, 2014Applicant: The Children's Hospital of PhiladelphiaInventor: Rodney M. Camire
-
Publication number: 20140248660Abstract: The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns.Type: ApplicationFiled: December 19, 2013Publication date: September 4, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Barbara ENENKEL
-
Patent number: 8822181Abstract: A method for forming a fusion protein that is expressed as a recombinant protein body-like assembly in host eukaryotic cells and organisms other than higher plants as host systems is disclosed. More particularly, peptides and proteins are fused to protein sequences that mediate the induction of recombinant protein body-like assembly (RPBLA) formation, are stably expressed and accumulated in these host cells after transformation with an appropriate vector. Methods for preparing the fusion protein are also disclosed.Type: GrantFiled: November 29, 2005Date of Patent: September 2, 2014Assignee: ERA Biotech S.A.Inventors: Margarita Torrent, Miriam Bastida, Pablo Marzábal, Blanca Llompart, Ma Dolores Ludevid
-
Patent number: 8822417Abstract: Variants of a parent albumin having altered plasma half-life compared with a parent albumin are described. Fusion polypeptides and conjugates including the variant albumin are also described. Embodiments include, but are not limited to, a polypeptide which is a variant of albumin, including one or more alterations at one or more positions corresponding to 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120 in SEQ ID NO: 2.Type: GrantFiled: May 4, 2012Date of Patent: September 2, 2014Assignee: Novozymes Biopharma DIC A/SInventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
-
Patent number: 8822180Abstract: There are provided a DNA construct comprising a suppressor tRNA gene of a non-eukaryote containing no internal promoter functioning in a eukaryotic cell, and a eukaryotic or bacteriophage promoter linked at the 5? end of the tRNA gene, a method for synthesizing a suppressor tRNA by using the DNA construct, and a process for producing protein incorporating a non-natural amino acid by using the same.Type: GrantFiled: April 30, 2012Date of Patent: September 2, 2014Assignee: RikenInventors: Shigeyuki Yokoyama, Kensaku Sakamoto, Nobumasa Hino, Takahito Mukai, Takatsugu Kobayashi
-
Publication number: 20140242692Abstract: The present invention relates to cellular proteins that are involved in toxicity and infection or are otherwise associated with the life cycle of one or more pathogens.Type: ApplicationFiled: December 11, 2011Publication date: August 28, 2014Inventors: Donald Rubin, Dana Borden Lacy
-
Publication number: 20140242637Abstract: The invention concerns the field of recombinant gene engineering. It concerns novel artificial introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel artificial intron sequences.Type: ApplicationFiled: December 19, 2013Publication date: August 28, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Barbara ENENKEL
-
Patent number: 8815583Abstract: Cell lines are provided for expressing peptidylglycine alpha-amidating monooxygenase (PAM), or one of its two catalytic domains. High levels of enzyme expression are achieved while utilizing a non-animal source, low protein tissue culture medium. A robust two-step downstream purification results in high enzyme purity. Resulting PAM, or its PHM catalytic domain, is used to catalyze the enzymatic conversion of X-Gly to X-alpha-hydroxy-Gly or X—NH2 (X being a peptide or any chemical compound having a carbonyl group to which a glycine group can be covalently attached). Methods of preparing preferred cell lines are also set forth.Type: GrantFiled: June 23, 2006Date of Patent: August 26, 2014Assignee: Enteris BioPharma, Inc.Inventors: Duncan A. Miller, Nozer M Mehta, Angelo P Consalvo
-
Patent number: 8815573Abstract: The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells. The invention also provides kits for use in the cultivation of a mammalian epithelial cell that comprise one or more containers, wherein a first container contains the culture medium of the invention. These kits may further comprise one or more additional containers containing one or more supplements.Type: GrantFiled: March 20, 2013Date of Patent: August 26, 2014Assignee: Life Technologies CorporationInventors: Stephen F. Gorfien, Richard Fike, Glenn P. Godwin, Joyce L. Wolanske, David A. Epstein, Dale Gruber, Don McClure, Paul J. Price
-
Publication number: 20140237632Abstract: Nucleic acid compositions encoding rapidly maturing fluorescent proteins, as well as non-aggregating versions thereof (and mutants thereof) as well as the proteins encoding the same, are provided. The proteins of interest are proteins that are fluorescent, where this feature arises from the interaction of two or more residues of the protein. The subject proteins are further characterized in that, in certain embodiments, they are mutants of wild type proteins that are obtained either from non-bioluminescent Cnidarian, e.g., Anthozoan, species or are obtained from Anthozoan non-Pennatulacean (sea pen) species. In certain embodiments, the subject proteins are mutants of wild type Discosoma sp. “red” fluorescent protein. Also of interest are proteins that are substantially similar to, or mutants of, the above specific proteins. Also provided are fragments of the nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and transgenic cells and organisms.Type: ApplicationFiled: January 21, 2014Publication date: August 21, 2014Inventors: BROOKE BEVIS, BENJAMIN GLICK
-
Patent number: 8809499Abstract: Provided is a fusion protein, which comprises human fibroblast growth factor 21 and glucagon-like-peptide-1 or its analogs. Also provided is the medicament composition comprising the fusion protein, which can be used for treating or preventing obesity, diabetes, hyperglycemia and hyperlipidemia etc.Type: GrantFiled: March 12, 2010Date of Patent: August 19, 2014Assignee: Chongqing Fagen Biomedical Inc.Inventors: Kai Fan, Zhiquan Zhao, Chun Zhang, Yong Chen, Hua Luo, Li Yang, Honghong Liu
-
Publication number: 20140227248Abstract: Methods and cell lines for overexpressing functional gamma-carboxylated proteins are disclosed.Type: ApplicationFiled: February 6, 2014Publication date: August 14, 2014Inventor: Reidar Wallin
-
Publication number: 20140227786Abstract: The present invention relates to methods of host cell transduction utilising ecotropic retroviral vector particles. The retroviral vector particle may comprise an envelope of Friend murine leukaemia virus, in particular the envelope encoded by molecular clone PVC-211 and the host cell may be engineered to recombinantly express the Rec1 receptor. The retroviral vector particles and methods of the invention can be used to introduce expressible polynucleotide sequences of interest into host cells with high efficiency. This results in protein production methods with higher yield (mg/L) and a reduction in manufacturing costs that could be used in a range of applications including for example, the production of therapeutic proteins, vaccines and antibodies.Type: ApplicationFiled: January 27, 2014Publication date: August 14, 2014Applicant: 4-Antibody AGInventor: Jörn Stitz
-
Publication number: 20140227294Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).Type: ApplicationFiled: December 23, 2013Publication date: August 14, 2014Applicant: ABBVIE INC.Inventors: Mark Anderson, Jieyi Wang, Archana Thakur, Debra Chao, Chung-Ming Hsieh, Qian Zhang, Edward B. Reilly, Enrico L. DiGiammarino, Kenton L. Longenecker, Russell A. Judge, David A. Egan, Charles W. Hutchins
-
Publication number: 20140220634Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.Type: ApplicationFiled: February 6, 2013Publication date: August 7, 2014Applicant: Janssen Biotech, Inc.Inventors: John Kehoe, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler, Jennifer Lee Gardiner
-
Publication number: 20140221618Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.Type: ApplicationFiled: April 15, 2014Publication date: August 7, 2014Inventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk Mclean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
-
Publication number: 20140220060Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.Type: ApplicationFiled: December 26, 2013Publication date: August 7, 2014Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.Inventors: Jan ZUR MEGEDE, Susan BARNETT, Ying LIAN, Susan ENGELBRECHT, Estrelita Janse VAN RENSBERG, Thomas J. SCRIBA
-
Publication number: 20140221613Abstract: The purpose of the present invention is: to provide an excellent protein which is further reduced in the binding property to an Fc region of an immunoglobulin and/or the binding property to an Fab region of the immunoglobulin in a weakly acidic region compared with that of a protein containing an extracellular domain of wild-type protein G, and which still keeps a high antibody-binding activity in a neutral region; and to capture and collect an antibody readily using the protein without denaturating the antibody.Type: ApplicationFiled: August 3, 2012Publication date: August 7, 2014Inventors: Shinya Honda, Hiroyuki Matsumaru, Hideki Watababe, Chuya Yoshida